Insider Selling: Alphatec Holdings, Inc. (NASDAQ:ATEC) CFO Sells 37,500 Shares of Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) CFO John Todd Koning sold 37,500 shares of the company’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $12.82, for a total value of $480,750.00. Following the transaction, the chief financial officer now owns 393,356 shares of the company’s stock, valued at $5,042,823.92. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

John Todd Koning also recently made the following trade(s):

• On Friday, March 1st, John Todd Koning sold 121,601 shares of Alphatec stock. The stock was sold at an average price of $13.30, for a total value of $1,617,293.30.

Alphatec Price Performance

ATEC stock traded up $0.20 during trading hours on Friday, hitting $12.44. 1,255,900 shares of the stock traded hands, compared to its average volume of 1,614,278. The stock has a 50-day simple moving average of $13.69 and a 200 day simple moving average of $13.46. Alphatec Holdings, Inc. has a one year low of $8.66 and a one year high of $19.14. The company has a market cap of $1.72 billion, a P/E ratio of -7.90 and a beta of 1.55. The company has a current ratio of 2.86, a quick ratio of 1.99 and a debt-to-equity ratio of 6.54.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Tuesday, February 27th. The medical technology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.09). The company had revenue of $138.00 million during the quarter, compared to analyst estimates of $131.90 million. During the same period in the prior year, the company earned ($0.33) earnings per share. The firm’s quarterly revenue was up 30.3% on a year-over-year basis. Equities analysts forecast that Alphatec Holdings, Inc. will post -1.1 earnings per share for the current year.

Institutional Investors Weigh In On Alphatec

Hedge funds have recently modified their holdings of the stock. BluePath Capital Management LLC purchased a new stake in Alphatec in the 3rd quarter worth about $29,000. RiverPark Advisors LLC purchased a new stake in Alphatec in the 3rd quarter worth about $53,000. Provence Wealth Management Group purchased a new stake in Alphatec in the 3rd quarter worth about $56,000. Van ECK Associates Corp purchased a new stake in Alphatec in the 3rd quarter worth about $113,000. Finally, Tidemark LLC purchased a new stake in Alphatec in the 4th quarter worth about $137,000. 66.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently commented on ATEC shares. Wells Fargo & Company started coverage on Alphatec in a research note on Friday, February 9th. They set an “overweight” rating and a $26.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research note on Monday, March 4th. Needham & Company LLC increased their price target on Alphatec from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, March 28th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $25.00 price target on shares of Alphatec in a research note on Wednesday, March 20th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.63.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.